

Marjolein P A Brekelmans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4427954/publications.pdf>

Version: 2024-02-01

12
papers

559
citations

1040056

9
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

966
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcome of patients with a vitamin K antagonist-associated bleeding treated with prothrombin complex concentrate. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 77-84.	2.3	6
2	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. <i>Thrombosis Research</i> , 2018, 162, 7-14.	1.7	20
3	Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. <i>Thrombosis and Haemostasis</i> , 2018, 118, 174-181.	3.4	11
4	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , 2018, 02, e1-e7.	1.4	5
5	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018, 39, 4208-4218.	2.2	267
6	Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 118-129.	2.1	47
7	Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1944-1951.	3.4	36
8	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2406-2414.	3.4	8
9	Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. <i>Thrombosis and Haemostasis</i> , 2017, 117, 809-815.	3.4	58
10	Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2016, 116, 155-161.	3.4	17
11	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e437-e445.	4.6	29
12	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e228-e236.	4.6	55